Daré Bioscience (NASDAQ:DARE) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.65 and traded as low as $3.18. Daré Bioscience shares last traded at $3.20, with a volume of 23,719 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The firm has a market cap of $27.84 million, a P/E ratio of -5.42 and a beta of 1.27. The firm has a 50 day simple moving average of $3.52 and a 200 day simple moving average of $3.65.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.